Bayer agrees to help make CureVac’s COVID-19 vaccine

BERLIN (Reuters) – German pharmaceutical giant Bayer said on Monday it will help CureVac produce its experimental COVID-19 vaccine, the latest drugmaker to offer up manufacturing capacity as supplies fall behind demand.

 

Bayer said it expects to produce 161 million doses of CureVac’s experimental vaccine, which is currently in late-stage testing, in 2022, its head of pharma Stefan Oelrich told a news conference. (Reporting by Caroline Copley; editing by Thomas Seythal)

 

facebookShare on Facebook
TwitterPost on X
FollowFollow us
PinterestSave

Related Posts

‘We have done ourselves proud’ . . . international community taking notice
‘We have done ourselves proud’ . . . international community taking notice

Wallace Ruzvidzo-Herald Reporter Zimbabwe’s resounding victory, which secured the country a non-permanent seat on the United Nations Security Council, is a win for the nation, President Mnangagwa has said. Speaking…

Continue reading
Zimbabwe’s global profile continues to soar
Zimbabwe’s global profile continues to soar

Zvamaida Murwira and Ivan Zhakata ZIMBABWE’s global profile continues to soar phenomenally since independence, with Harare’s election into the United Nations Security Council for a non-permanent seat, showing that the…

Continue reading

Leave a Reply

Your email address will not be published. Required fields are marked *

×
×